Clik here to view.
Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in...
CHENGDU, China Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient was...
View ArticleClik here to view.
Brii Biosciences Expands Infectious Disease Pipeline
BEIJING & DURHAM, N.C. Brii Biosciences, a clinical-stage company committed to serving patients’ needs and improving public health in China and around the world, today announced a series of...
View ArticleClik here to view.
PENTAX Medical Launches DEC™ HD Duodenoscope in the United States
MONTVALE, N.J. PENTAX Medical, a healthcare industry leader in diagnostic and therapeutic endoscopy, has announced the United States launch of its DEC™ HD Duodenoscope, an advanced, high-definition...
View ArticleClik here to view.
Phenomics Health Inc. 收购专利药物代谢组技术
密西根州安娜堡 (美国商业资讯)–基于生物信息学平台的精准医学公司Phenomics Health Inc.今天宣布，其已收购总部位于美国田纳西州富兰克林的Precera Bioscience公司的专利药物代谢组技术组合。 Phenomics Health计划将该新技术与自身的专利先进药物基因组平台相整合，在患者对用药的潜在和实际应答方面，向医疗保健提供者提供比现有技术更完整的图景。...
View ArticleClik here to view.
Zymeworks在ESMO亚洲大会上宣布推进与百济神州的临床合作并公布ZW25用于治疗HER2呈阳性癌症患者的1期临床研究更新数据
新加坡 (美国商业资讯)– Zymeworks Inc. (NYSE: ZYME)是一家处于临床开发阶段、专注于多功能治疗药物开发的生物制药公司。公司今天宣布在11月22 – 24日于新加坡召开的2019年ESMO 亚洲大会上，韩国首尔大学教授兼该研究的研究者Do-Youn...
View ArticleClik here to view.
Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and...
SINGAPORE Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated Phase 1 data for single agent ZW25 in heavily...
View ArticleClik here to view.
Heartseed Raises $26M in Series B Funding to Accelerate Development of...
TOKYO Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for the treatment of heart failure (HF), today announced it has raised 2.8 Billion-yen...
View ArticleClik here to view.
Phenomics Health Inc. Acquires Patented Pharmacometabolomic Technology
ANN ARBOR, Mich. Phenomics Health Inc., a bioinformatics platform-based precision medicine company, today announced it has acquired the patented pharmacometabolomic technology portfolio of Precera...
View ArticleClik here to view.
FDA grants Breakthrough Therapy Designation to Usona Institute’s psilocybin...
MADISON, Wis. Usona Institute has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for psilocybin in the treatment of major depressive disorder (MDD)....
View ArticleClik here to view.
Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib)...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced updated data from the Phase 3 ALTA-1L trial, which evaluated ALUNBRIG versus crizotinib...
View ArticleClik here to view.
パンセリックスが母子の免疫賦活栄養分野でAPS BioGroupとビタデイリーが数百万ドル規模の独占契約を締結したと発表
米コロラド州ボルダー （ビジネスワイヤ） — ウシ初乳ベースの治療薬が持つ可能性の実現に傾倒するバイオテクノロジー企業のパンセリックスは本日、当社の完全子会社APS...
View ArticleClik here to view.
Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502 / NYSE:TAK) (“Takeda”) today announced that updated results from the ongoing pivotal Phase 3 Tetravalent...
View ArticleClik here to view.
AVITA Medical and the Gates Center for Regenerative Medicine at the...
VALENCIA, Calif., MELBOURNE, Australia & AURORA, Colo. AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical...
View ArticleClik here to view.
Celltrion Healthcare receives EU marketing authorisation for world’s first...
INCHEON, South Korea Celltrion Healthcare today announced that the European Commission has approved Remsima SC™ (CT-P13 SC, biosimilar infliximab) for patients with RA.1 Remsima SC™ is the world’s...
View ArticleClik here to view.
Poxel Announces Positive Topline Results for Imeglimin Phase 3 Trial (TIMES 3...
LYON, France POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes, announced...
View ArticleClik here to view.
GN CORPORATION: Vision Restored with Corneal Cell Transplant Using a Nano...
TOKYO A novel cell transplantation method to treat corneal endothelial diseases such as bullous keratopathy using a nano-composite gel sheet developed by Japanese scientists was granted Indian...
View ArticleClik here to view.
武田呈报的ALK+ NSCLC长期数据显示，ALUNBRIG® (brigatinib)在2年随访期之后继续展示一线治疗中的优效性
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(TSE:4502/NYSE:TAK)今天发布了3期ALTA-1L试验的更新数据，该试验评估ALUNBRIG...
View ArticleClik here to view.
Merck’s KEYTRUDA® (pembrolizumab) Now Approved in China for First-Line...
KENILWORTH, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by the National Medical Products...
View ArticleClik here to view.
EOS imaging Announces the Upcoming Launch of EOSedge™, Its New Generation...
PARIS Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191126005639/en/ (Photo: Business Wire) EOS imaging (Paris:EOSI)...
View ArticleClik here to view.
武田薬品が第68回米国熱帯医学会（ASTMH）年次集会でデング熱ワクチン候補のピボタル第3相試験の18カ月データを発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:4502 / NYSE:TAK）（以下、武田薬品）は本日、当社のデング熱ワクチン候補（TAK-003）を検討するために実施中のピボタル第3相「デング熱に対する4価ワクチン予防接種の有効性試験」（Tetravalent Immunization against Dengue Efficacy...
View Article